Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opicinumab Add-On Therapy in Relapsing Multiple Sclerosis
2017-001224-22Phase 2Unknown
- Sponsor
- Biogen
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Opicinumab add-on arm with Placebo add-on arm (2 arms). Status: unknown.
02
Drugs
opicinumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2017-001224-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001224-22.